EWM
ACRS icon

Empirical Wealth Management’s Aclaris Therapeutics ACRS Stock Holding History

Empirical Wealth Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85K Buy
+16,072
New +$71.7K ﹤0.01% 1045

Other funds holding ACRS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
CAL
Capital Advisors Ltd Shaker Heights, Ohio $991M AUM 19.82% 1-Year Est. Return

Empirical Wealth Management's ACRS Position: Q2 2026 in Review

Empirical Wealth Management opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 16,072 shares worth $85K. The stake represents ﹤0.01% of the portfolio and ranks #1045 among its holdings.

7 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Empirical Wealth Management held 16,072 shares of Aclaris Therapeutics worth $85K as of Q2 2026.
  • Aclaris Therapeutics was a new Empirical Wealth Management position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Empirical Wealth Management's portfolio in Q2 2026, its #1045 holding.
  • 7 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.